Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations

Table 1 Baseline characteristics of study participants

Characteristic	Testosterone group (n = 20)	Placebo group (n = 19)	P value
Age (yr)	62 (58-67)	60.4 (6.5)	0.5
Duration of type 2 diabetes (yr)	8 (6-14)	7 (5-9)	0.2
Insulin therapy, n (%)	3 (15)	2 (10.5)	> 0.9
Weight, kg	92 (86-101)	98 (92-105)	0.15
BMI, kg/m2	30.3 (27.3-31.9)	32.0 (29.7-35.4)	0.14
Waist circumference, cm	106 (102-116)	112 (106-119)	0.4
Fat mass, g	30788 (24875-38117)	31758 (29332-35286)	0.8
Lean mass, g	57090 (51658-62688)	62140 (66226-65844)	0.029
ALT, IU/L	34 (26-38)	32 (25-52)	0.8
ALP, IU/L	72 (60-82)	58 (54-69)	0.057
GGT, IU/L	30 (21-38)	32 (25-45)	0.5
TT, nmol/L (ECLIA)	9.8 (7.2-12.0)	7.8 (6.0-10.8)	0.2
cFT, pmol/L (ECLIA)	216 (151-272)	176 (146-224)	0.3
SHBG, nmol/L	28 (20-34)	28 (23-32)	0.8
LH, IU/L	4.5 (3.4-7.0)	4.3 (3.4-6.0)	0.7
Fasting glucose, mmol/L	8.9 (6.8-10.3)	8.5 (7.7-9.8)	0.6
HbA1c, %	6.6 (6.4-7.2)	7.0 (6.7-7.3)	0.071
Cholesterol, mmol/L	4.4 (4.0-5.0)	4.6 (4.0-4.9)	> 0.9
LDL, mmol/L	2.4 (2.0-3.0)	2.7 (2.0-3.0)	0.7
HDL, mmol/L	1.2 (1.0-1.4)	1.0 (0.7-1.2)	0.03

Data are median (IQR). ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TT: Total testosterone; cFT: Calculated free testosterone; SHBG: Sex hormone-binding globulin; LH: Luteinising hormone; LDL: Low-density lipoprotein; HDL: High density lipoprotein.